About the Study
This study is designed to evaluate the safety and effectiveness of petrelintide, an investigational injection, for chronic weight management in adults who are overweight or obese, with cardiovascular disease. Petrelintide is an “investigational” drug because it has not been approved by the Food and Drug Administration (FDA).
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 50% chance you will receive the study treatment and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be in this study for at least 1 year and 7 months and up to 3 years which will include a screening period, a treatment period, and a follow up period. The study will require up to 20 in-clinic visits and 12 remote visits. If you qualify and choose to participate, you may be compensated up to $3,730 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.